Flash | 23 Jul 2026 03:38:16 ET │ 10 pages Chugai Pharmaceutical (4519.T) Implications of results at Roche and Galderma CITI'S TAKE Roche and Galderma announced results at 14:00 PM Japan time. We discuss implications for Chugai. Roche's Japan sales grew 11% in CER terms, with Q1 up 14% and Q2 up 9%, for a solid performance. Sales of Hemlibra, Lunsumio, Elevidys, and Vabysmo were good as well. Sales to third parties were also strong, due likely in part to strong Nemluvio sales at Galderma (Q2: $266mn, Q1: $1 ...